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ABSTRACT 
 
Leptospirosis is a worldwide zoonosis infection caused by Gram-negative 
bacteria from the genus of Leptospira. Eight pathogenic species of Leptospira have 
been identified and there are more than 250 serovars that can cause leptospirosis to 
human and animals. Due to the indistinguishable symptoms of the disease, leptospirosis 
is often misdiagnosed, resulting to death if antibiotic treatment is not given 
immediately. Prophylactic vaccine can reduce the mortality rate resulting from the late 
treatment. However, the existing vaccines for leptospirosis are serovar-specific and can 
only provide limited protection to human. Therefore, a new and more effective vaccine 
is urgently needed. The vaccine can be developed in shorter time with reduced cost 
through rational design and in silico approach by maximizing the use of the abundant 
information on the sequences of leptospiral antigenic proteins and the growing number 
of bioinformatics tools. The objective of this research is to perform an in silico analysis 
to develop a vaccine from the peptide sequence of leptospiral outer membrane protein, 
LigB. The predicted peptide-based vaccine, which requires experimental validation in 
the future, is hoped to be effective against all pathogenic serovars of Leptospira and 
ultimately provide us immunity to leptospirosis.  
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ABSTRAK 
 
 Leptospirosis, yang merupakan jangkitan zoonosis di seluruh dunia, 
disebabkan oleh bakteria Gram-negatif daripada genus Leptospira. Lapan spesies 
Leptospira yang bersifat patogenik telah dikenal pasti dan terdapat lebih daripada 250 
serovars yang boleh menyebabkan leptospirosis kepada manusia dan haiwan. Oleh 
sebab gejala penyakit tersebut sukar untuk dibezakan, kesilapan dalam diagnosis 
penyakit ini seringkali berlaku. Hal ini akan membawa maut, jika rawatan antibiotik 
tidak diberikan dengan segera. Vaksin yang merupakan agen pencegahan boleh 
mengurangkan kadar kematian yang disebabkan oleh leptospirosis yang lewat dikesan. 
Namun, vaksin yang sedia ada untuk leptospirosis hanya berkesan untuk satu serovar 
sahaja dan hanya dapat memberi perlindungan yang terhad untuk manusia. Oleh itu, 
vaksin baharu yang lebih berkesan amat diperlukan. Vaksin ini boleh direka dalam masa 
yang lebih singkat dengan kos yang rendah dengan menggunakan kaedah ‘rational 
designing’ dan ‘in silico’ dengan memanfaatkan maklumat peptida dalam protein 
Leptospira sp. yang bersifat antigenik dan menggunakan bantuan perisian 
bioinformatik. Objektif kajian ini adalah untuk menjalankan analisis ‘in silico’ untuk 
mencipta vaksin dari urutan peptida protein membran luar Leptospira sp. iaitu LigB. 
Vaksin baharu yang berasaskan peptida ini perlu diuji dengan eksperimen dan 
diharapkan berkesan terhadap semua serovar Leptospira yang patogenik dan juga dapat 
memberikan kita perlindungan daripada leptospirosis. 
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CHAPTER 1 
 
INTRODUCTION AND LITERATURE REVIEW 
 
1.1 Leptospirosis & Leptospira sp. 
 
Leptospirosis is a worldwide zoonosis that is caused by pathogenic Leptospira sp. The 
bacterial disease is estimated to pose huge global burden on developed and developing 
countries with more than 500,000 severe cases per year around the world (Silva et al, 
2007). The first leptospirosis case in Malaysia was documented in 1925 (Fletcher, 1928) 
involving rubber estate workers and rural inhabitants. Most of the cases of human 
leptospirosis worldwide have been attributed to rodents, which are believed to be the 
principal reservoir of leptospirosis (Miller et al, 1991).  
 
The pathogenic leptospires are harboured in the renal tubules of the wild and 
domesticated mammals, which serve as maintenance hosts, before the spirochaetal 
bacteria are shed in the animal urine into the environment. The bacteria can penetrate 
through abraded skin or mucosal membrane of human following accidental, 
occupational, or recreational exposure to the urine from the infected animals, or 
contaminated water sources (Faine et al, 1999). The patients who are infected with 
pathogenic Leptospira sp have shown diverse clinical manifestations ranging from 
asymptomatic infection, mild febrile symptoms to severe multi-organ failure. If 
immediate antibiotic treatment is not sought, mortality rate can increase from 5 to 40% 
(Farr, 1995).   
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 There are at least 19 species of Leptospira sp that have been documented, with 8 
species considered to be pathogenic while the rest are saprophytic. The eight pathogenic 
species, namely, L. interrogans, L. borgpetersenii, L. santarosai, L. noguchii, L. weilli, 
L. kirscheneri, L. alexanderi and L. alstoni are reported to be the main agents of 
leptospirosis (Evangelista & Coburn, 2010; Cinco, 2010). Phenotypic classification 
based on serology has revealed that there are more than 200 serovars of pathogenic 
leptospires (Faine et al 1999; Goncalves-de-Albuqurque et al., 2012).  
 
A well-known Leptospira, L. biflexa is a free-living, saprophytic strain that 
causes no infection despite being genetically and morphologically similar to the 
pathogenic strain (Nascimiento et al, 2004). With the genome size of approximately 4.6 
Mbp (Ricaldi et al, 2012, pathogenic Leptospira is indisputably well equipped with 
impressive arsenal of proteins at its disposal to facilitate host tropism as well as 
successfully evade host the immune response, ultimately guaranteeing its survival in the 
body of the host. Although the pathogenesis of leptospiral infection at molecular level 
remains enigmatic at the moment, several candidate virulence factors have been 
identified and implicated in the pathogenesis of leptospirosis (Evangelista and Coburn, 
2010).  
 
1.2 Human immune system and Leptospira sp. 
 
Once a pathogenic Leptospira sp. invade the first line of defence in human body, the 
extracellular bacterium will be engulfed by professional antigen presenting cells (APC), 
for example dendritic cells and macrophages, and it will be trapped in an endocytic 
vesicle. The trapped bacterium is then digested by hydrolytic enzyme in the lysosome of 
APC into smaller peptide fragments. The particular immune cells continually synthesize 
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an important protein, major histocompatibility complex (MHC) Class II molecule, or 
human leukocyte antigen (HLA) molecule in human, and store the protein in a vesicle. 
Then, the vesicle containing the leptospiral peptides merges with a vesicle containing 
HLA. Only one of the pathogenic peptide fragments can implant itself into the binding 
groove of the Class II molecules to form a peptide-MHC Class II complex, before the 
complex is shuttled to the plasma membrane of APC to be presented to helper T cell, 
which will initiate a specific and appropriate immune response to the pathogenic 
bacteria (Weenink & Gautam, 1996). 
 
The damaging effect of leptospirosis is partly due to the release of various 
inflammatory mediators and serum proteins that make up the host’s immune response to 
the bacteria (Chirathaworn & Kongpan, 2014). Although leptospirosis can be treated 
with antibiotics, the symptoms of leptospirosis may vary and resemble those of other 
diseases, making leptospirosis prone for misdiagnosis. Hence, prophylactic vaccine for 
leptospirosis is required to build the immunity of an individual before the actual 
infection occurs. The existing vaccines for leptospirosis have been developed and 
shown disadvantages like suboptimal protection and failure to prevent the disease 
(Levett, 2001; Wang et al, 2007). There is an urgent need for an improved vaccine that 
can give broader protection and is effective against all pathogenic serovars of 
Leptospira.  
 
1.3 In silico screening for vaccine 
 
The adaptive human immune response, which is highly specific against a particular 
pathogen, is induced when the immune receptors from T cells are able to recognise an 
epitope, which is a molecular structure of peptides that is presented by MHC Class II 
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molecules. Only peptides interacting with Class II molecules above a certain affinity 
threshold are likely to be recognised by T cells and generate a specific immune response 
(Sette et al, 1994). Therefore, identification of the correct epitope is the key step toward 
the development of a new and effective vaccine. However, epitope identification and 
mapping are challenging areas of vaccine research due to the overwhelming variation in 
MHC Class II or HLA alleles in human and limitless permutations of peptide sequence 
in a single epitope. Thankfully, the epitope prediction can be done computationally and 
the in silico method has proven to significantly shrink the vast sample space and allow 
us to rationally designed a vaccine before the effectiveness of the vaccine can be further 
tested in vitro or in vitro (De Groot et al, 2009).  
 
Prediction of which peptides can bind MHC molecules is commonly used to 
assist in the identification of T cell epitopes. Several tools of epitope prediction have 
been developed, nevertheless, large numbers of different MHC molecules, each 
associated with different predictive tools, tool generation and evaluation can be a very 
resource intensive task. These tools made full use of the available data sets obtained 
from laboratory experiments as training data and few mathematical algorithms to make 
predictions of the highly likely epitope to be presented by HLA molecules. To date, 
several methods have been widely used to predict class II epitopes such as simple 
binding motifs, quantitative matrices, Average Relative Binding (ARB) matrix (Bui et 
al, 2005), Hidden Markov Model (Lacerda et al, 2010) and artificial neural networks 
(Nielsen et al, 2010).  
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1.4 Target protein for leptospirosis vaccine 
 
Secreted and surface-exposed antigens are mostly antigenic and susceptible to antibody 
recognition and T-cell killing (Wang et al, 2001). Owing to this fact, outer-membrane 
proteins (OMPs) from pathogens have garnered huge interests due to their potential in 
becoming the primary vaccine targets  (Amineni et al, 2010; Cafardi et al 2013). By far, 
in silico vaccine development has been successful in the design of vaccine for Hepatitis 
B (from HBsAg protein), Influenza (from HA and NA proteins) and Human Papilloma 
Virus (from capsid protein) (Delany et al, 2013).  
 
To design a peptide-based vaccine for leptospirosis, it is important to choose an 
antigenic and immunogenic outer membrane protein (OMP) that is shared by all 
pathogenic serovars of Leptospira because the antigenic peptide is supposed to be able 
to elicit broader protection against all pathogenic serovars. It has been suggested that 
the outer membrane proteins from Leptospira sp. have the potential advantage of 
inducing comprehensive immunity besides being well-conserved and main virulence 
factors toward host tissues. Several leptospiral transmembrane OMPs have been 
identified, for example, OmpL1 (Haake et al, 1999), LipL36 (Haake et al, 2000), 
LipL32 (Haake et al, 2000), LipL21 (Cullen et al, 2005), LipL46 (Matsunaga et al, 
2003), LenA (Verma et al, 2010), Loa22 (Matsunaga et al, 2003) and Omp52 (Haake et 
al, 1999).  
 
Extensive research has been done on the potential of the aforementioned 
proteins as the vaccine candidate for leptospirosis, however, the effectiveness of the 
proteins as peptide-based vaccine for leptospirosis remains inconclusive (Haake et al, 
1999; Guerreiro et al, 2001). One of the recently discovered OMPs from Leptospira sp., 
	   6 
namely LigB protein (Matsunaga et al, 2003), was suggested to be an attractive target 
for leptospirosis vaccine (Raja & Natarajaseenivasani, 2014). ligB gene has been shown 
to be one of the genes that is upregulated under physiological osmolarity (Cinco, 2010). 
The protein has also been found in the sera of human patients with leptospirosis and it 
has been demonstrated to provide almost 100% cross-protection in mice (Koizumi et al, 
2004). Therefore, the LigB protein is a suitable target protein for leptospirosis vaccine. 
  
 LigB is one of Leptospiral Immunoglobulin-like proteins, which is a member of 
the bacterial immunoglobulin-like (Big) protein super family. The outer membrane 
protein is able to mediate interaction of bacteria with host cell, which leads to cell 
attachment and host invasion. The protein assists bacterial admission into the host cell 
by mediating the adherence of leptospires to the host’s extracellular matrix, including 
fibronectin, fibrinogen, collagen, laminin (Lin et al, 2007) and kidney epithelial cells 
(Cinco, 2010). The LigB protein, which is exclusively found in pathogenic Leptospira 
sp, is predicted to have 12 tandem bacterial immunoglobulin-like repeated domains 
(Figure 1). The solution structure of the twelfth immunoglobulin-like (Ig-like) repeat 
domain from LigB (LigB-12) was identified to comprise mainly of β-strands that form a 
β-sandwich based on a Greek-key folding arrangement by using an NMR spectroscopy 
(Ptak et al, 2014).  
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Figure 1: A schematic diagram showing the twelve domains within the LigB protein. The N-terminal 630 amino acids of LigB, 
which covers the first 6 ½ Ig-like domains, are highly conserved between LigB and its corresponding LigA protein. The remaining 
C-terminal domains are variable. The twelfth domain is connected to non-Ig-like domain. N: N-terminal, C: C-terminal (Ptak et al, 
2014) 
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1.5 Objective of the study 
 
Having identified a relatively new potential antigenic OMP from pathogenic Leptospira 
sp., an in silico analysis was performed with the help of several mostly referenced 
bioinformatics tools to identify several candidates for peptide-based vaccine for 
leptospirosis using the LigB as the antigenic protein. The vaccine is hoped to evoke T 
cell response and give a broader immune protection to human against all pathogenic 
serovars of Leptospira sp. Firstly, a sequence-based analysis was done to identify the 
best peptide that has the motif of a T cell epitope, which is more likely to initiate 
immune response from T cells. Secondly, a structure-based analysis was done to 
computationally verify that the best peptide vaccine candidate could bind to a chosen 
HLA molecule. The predicted peptide sequence for the vaccine was established to allow 
an experimental validation in the future. 
 
 
 
 
 
 
 
 
 
 
 
 
	   9 
CHAPTER 2 
 
METHODOLOGY 
 
2.1 Selection of LigB protein sequences 
 
The LigB sequence of L. kirschneri RM52 (AAP04736.1), deposited by Matsunaga et 
al, 2003 was retrieved from NCBI Protein database. The sequence of the protein was 
saved in the FASTA format. Using the LigB protein sequence, a BLASTP search was 
performed against UniProtKB database using the default parameters to search for 
homologous sequences. Only protein sequences that were named LigB and that 
originated from pathogenic Leptospira sp. were considered. The list was further 
trimmed by selecting only sequences that had at least 60% identity to the queried 
sequence and had a clear nomenclature i.e. the sequences have serovar and species 
clearly stated. The details of the sequences fulfilling the criteria are summarised in 
Chapter 3.  
 
2.2 Multiple sequence alignment & divergence analysis 
 
All the selected sequences of LigB, which were saved in a single FASTA file, were 
subjected to multiple sequence alignment using ClustalW algorithm implemented in 
MEGA v.6.06 using default parameters. The conserved residues were visualised and 
identified using Chimera software from the aligned sequences. Using MEGA v.6.06, a 
Neighbour Joining tree was constructed with 1000 bootstraps at uniform divergence 
rates with distance ‘p’ as the evolutionary model and with a data subset to use with 
gaps/ missing data treatment as complete deletion.  
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2.3 Prediction of the most antigenic protein 
 
The most antigenic protein of all the selected LigB sequences was predicted using an 
online antigen prediction server, VaxiJen v.2.0 server (http://www.ddg-
pharmfac.net/vaxijen/VaxiJen/VaxiJen.html). The server is especially designed to 
predict the antigenicity of the protein based on the physicochemical properties of the 
amino acid (Doytchinova & Flower, 2007). The set of 32 LigB protein sequences was 
entered and a target organism was set as ‘Bacteria’. The default threshold of 0.4 was 
used for the antigenicity prediction. The outputs given by the server were the 
antigenicity score and the status of the sequence i.e. whether the sequence is a probable 
antigenic or non-antigenic.  
 
2.4 Prediction of the T cell epitopes 
 
The sequence of the most antigenic protein was fed into NetMHC v.2.2 server 
(http://www.cbs.dtu.dk/services/NetMHCII/). The length of the peptide was set to be 
‘15’. This step was performed to generate 15-mer peptides, which mimics the natural 
process of bacterial degradation in the endocytic vesicle of APC. The server is also able 
to predict the binding of the peptides to HLA-DR, HLA-DQ, HLA-DP, and mouse 
MHC class II alleles based on the artificial neural network method (Nielsen et al, 2007; 
Nielsen & Lund, 2009). Only human MHC class II alleles were used in the analysis, 
since the aim of the current study is to design a vaccine for human. All the 14 HLA-DR 
alleles, 5 HLA-DP alleles and 6 HLA-DQ alleles, which were used in the analysis, were 
summarised in Table 2.1. 
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Table 2.1: The HLA alleles used in the prediction of T cell epitope analysis. 
HLA-DR HLA-DRB1*0101 
HLA-DRB1*0301 
HLA-DRB1*0401 
HLA-DRB1*0404  
HLA-DRB1*0405 
HLA-DRB1*0701 
HLA-DRB1*0802 
HLA-DRB1*0901 
HLA-DRB1*1101 
HLA-DRB1*1302 
HLA-DRB1*1501 
HLA-DRB3*0101 
HLA-DRB4*0101 
HLA-DRB5*0101 
HLA-DP HLA-DPA1*0103-DPB1*0401 (HLA-DPA1*01-DPB1*0401) 
HLA-DPA1*0103-DPB1*0201 
HLA-DPA1*0201-DPB1*0101 HLA-DPA1*0201-DPB1*0501 
HLA-DPA1*0103-(HLA-DPB1*0301/DPB1*401) 
HLA-DPA1*0301-DPB1*0402 
HLA-DQ HLA-DQA1*0101-DQB1*0501 
HLA-DQA1*0102-DQB1*0602 
HLA-DQA1*0301-DQB1*0302 
HLA-DQA1*0401-DQB1*0402 
HLA-DQA1*0501-DQB1*0201 
HLA-DQA1*0501-DQB1*0301 
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The outputs given were the peptide sequences, affinity score (expressed as IC50 
value in nM) and bind level (weak binder or strong binder). The default threshold of 
500 nM was used to classify the peptides into binders and non-binders. Only high 
binding peptides (having an IC50 value below 50 nM) were filtered and selected. The 
strong binding peptides would be known as T cell epitopes as the peptides were 
predicted to have high affinity for the selected HLA molecules, hence more likely to be 
presented to T cells in the context of MHC Class II molecules. The strong binders were 
checked whether they covered all three types of HLA molecules, namely HLA-DP, 
HLA-DR, and HLA-DQ. Only strong binders that were found to be associated to all 
three HLA types were shortlisted for further analysis.  
 
2.5 Mapping of T cell epitopes to conserved regions 
 
All the shortlisted T cell epitopes from the most antigenic protein sequence were 
mapped to the conserved residues of the aligned LigB protein sequences. To qualify as a 
good peptide-based vaccine, the peptide should be a T cell epitope and it ideally needs 
to be as identical as possible to the conserved residues in the antigenic protein (Bui et 
al, 2007). An epitope conservancy analysis was performed using epitope conservancy 
tool available in IEDB analysis resource and is available at 
(http://tools.immuneepitope.org/tools/conservancy/iedb_input). The conservancy level 
of each potential epitope was calculated by looking for identity in all the 32 LigB 
sequences and the server was able to compute the identity score of the epitope to the 
consensus residues. 
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The peptide/ T cell epitope with the highest percentage identity to the conserved 
residues was selected as the best vaccine candidate and would be used for docking 
analysis. The consensus sequence that corresponds to the T cell epitope was considered 
to be the best peptide-based vaccine candidate. The peptide sequence was then mapped 
to the whole 3D structure of LigB protein predicted by RaptorX server 
(http://raptorx.uchicago.edu/) and the location of the peptide was predicted whether it is 
located in the part of the protein that is exposed to the external environment by 
TMHMM v2.0 server (http://www.cbs.dtu.dk/services/TMHMM/). This step was taken 
to ensure that the part of the antigenic protein is exposed and accessible to the immune 
cells. 
 
2.6 Rigid docking of peptide vaccine to HLA molecule 
 
A rigid docking analysis was performed between the best candidate of peptide vaccine  
and a chosen HLA molecule. Prior to the docking, two PDB files (for HLA molecule 
and peptide vaccine) were prepared. The 3D structure of the peptide vaccine was 
predicted and designed using the PEP-FOLD Peptide Structure Prediction server at the 
RPBS mobile portal (Thévenet et al, 2012). The best model provided by the server was 
validated by PROCHECK analysis. A crystal structure of HLA-DR1 molecule, which 
was to be docked with a peptide vaccine candidate, was retrieved from Protein Data 
Bank (PDB) server with the ID of 1KLU. The original peptide (staphylococcal 
enterotoxin C3 variant 3B2), which was complexed with the HLA molecule, was 
excluded using Chimera software, leaving only α- and β-chains.  
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For docking analysis, the two PDB files (the HLA-DR1 as receptor protein and 
the peptide vaccine as ligand protein) were uploaded onto GRAMM-X Protein-Protein 
Docking server v.1.2.0. The server uses Fast Fourier Transformation (FFT) 
methodology for the global search of the best rigid body conformations, followed by the 
refinement optimization in continuous coordinates and rescoring with several 
knowledge-based potential terms (Tovchigrechkov et al, 2006). The analysis returned 
with a PDB file with 10 possible configurations of the peptide binding to the HLA 
molecule. The final and best conformation of the peptide binding to the HLA molecule 
was processed with Chimera. The molecular interaction between the peptide vaccine 
and the HLA molecule was predicted using LigPlot v.4.5.3 program (Wallace et al, 
1995). The interaction between the residues of the peptide vaccine and the residues in 
the binding groove of HLA molecule was noted and evaluated. 
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CHAPTER 3 
 
RESULTS 
 
3.1 List of LigB sequences 
 
A total of 32 sequences of LigB protein from different pathogenic serovars have been 
selected (Table 3.1). Analysis of antigenicity revealed that all the sequences were 
antigenic (met the criteria of default threshold level, ≥ 0.4, in VaxiJen v.2.0).  
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Table 3.1: The list of all LigB protein sequences from pathogenic serovars of Leptospira sp. that have been used in the analysis.  
UniProt ID Species Serovar Strain Length (aa) Source 
Antigenicity 
score 
Q04YJ5 borgpetersenii Hardjo-bovis L550 1912 Cattle 0.5854 
Q04UY1 borgpetersenii Hardjo-bovis JB197 1896 Cattle 0.5846 
M6F3M0 kirschneri Bulgarica Nikolaevo 1916 Human 0.5426 
M6SBP2 interrogans Copenhageni HAI0188 1890 Human 0.5392 
K6JSN9 interrogans Icterohaemorrhagiae Verdun LP 1890 Human 0.5391 
Q72V39 interrogans Copenhageni Fiocruz L1-130 1890 Human 0.5352 
M6R7K6 interrogans Pomona UT364 1889 Human 0.5315 
M6HL92 interrogans Zanoni LT2156 1560 Human 0.5308 
K6I198 interrogans Canicola Fiocruz LV133 1889 Human 0.5277 
M6K1Q5 interrogans Pyrogenes L0374 1560 Human 0.5261 
B5TXC6 interrogans Pomona pLPLIGB 1889 Pig 0.5257 
C0J1Q6 interrogans Kennewicki PO-06-047 1889 Horse 0.5255 
G7QKX4 interrogans Lai IPAV 1889 Human 0.5249 
Q8EZS3 interrogans Lai 56601 1889 Human 0.5249 
M5UHA3 interrogans Pomona CSL10083 1844 Sea lion 0.5248 
K6F9Q2 interrogans Pomona Pomona 1889 Human 0.5243 
J7UHZ2 interrogans Bulgarica Mallika 1560 Human 0.5237 
M6A6I9 interrogans Pomona CSL4002 1846 Sea lion 0.5224 
M6PJ88 interrogans Grippotyphosa UI12764 1606 Human 0.5199 
T0FPW9 noguchii Panama CZ214 1930 Opossum 0.5195 
K8H670 kirschneri Grippotyphosa Moskva 1886 Human 0.5173 
M6KST2 interrogans Medanensis L0448 1889 Human 0.517 
M6NG55 interrogans Pyrogenes R168 1889 Human 0.5161 
Q7X504 kirschneri Grippotyphosa RM52 1886 Human 0.516 
K8JXB9 interrogans Grippotyphosa UI08368 1849 Human 0.5159 
K8IAH3 kirschneri Valbuzzi 200702274 1886 Human 0.5147 
M6QEZ6 interrogans Medanensis UT053 1889 Human 0.5147 
K8J0U3 interrogans Bataviae L1111 1889 Human 0.5137 
M6I6K5 kirschneri Bim 1051 1886 Dog 0.5126 
K8IQP7 interrogans Pyrogenes 2006006960 1487 Human 0.5123 
M7A596 interrogans Pyrogenes 2007001872 1889 Human 0.5095 
M6F4P4 kirschneri Bim PUO1247 1842 Human 0.5062 
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3.2 Conserved residues of LigB proteins 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1: The consensus residues in all the 32 aligned LigB sequences from pathogenic serovars of Leptospira sp. The grey bar 
illustrates the degree of amino acid conservations. The red letters written in capital represent highly conserved amino acids while the 
purple red letters written in capital represent moderately conserved residues. The small, black-coloured letters are residues with low 
conservation. The visualisation of the conserved regions was done with Chimera software. 
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Figure 3.1, continued. 
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3.3 Phylogenetic tree 
 
Figure 3.2: The phylogram illustrates, by bootstrap-based topology, the evolutionary relationship between all the LigB sequences 
from different pathogenic serovars of Leptospira sp. For the sake of brevity, the initial lowercase letters have been used to indicate 
the respective species, to which each serovar belongs: i. L. interrogans; k, L. kirschneri; n: L. noguchii, b: L. borgpetersenii. The 
bootstrap consensus values are indicated over each root. The phylogram, which was constructed by using the Neighbour-Joining 
algorithm, based on the LigBp protein sequences, demonstrates the clustering of serovars within the species. 
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3.4 Putative T cell epitopes 
 
It has been predicted that there were 140 peptides associated with HLA-DP alleles, 456 
peptides associated with HLA-DQ alleles, and 1526 peptides associated with HLA-DR 
alleles in the most antigenic protein sequence (Q04YJ5).	  Out	  of	  2122	  peptides/	  T	  cell	  epitopes,	  only	  seven peptides were predicted to be able to interact with the three types 
of MHC class II alleles (Figure 3.3). These seven 15-mer peptides were considered to 
be the most potential epitopes for MHC class II alleles (Table 3.2). 
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Figure 3.3: The sequence of the most antigenic protein (from serovar Hardjo-bovis str. L55) contains seven T cell epitopes, as 
predicted by NetMHCII v2.2. The T cell epitopes are bolded and coloured red. Three of the seven sequences of T cell epitopes 
overlap with each other. 
 
 
 
 
>Q04YJ5 (L. borgpetersenii Hardjo-bovis str. L550) 
 
MKKIFSIFLSLFFQGCMVWPLVVGAVGLSTGNKGDGNNPFLFLLGIASDPVITRIELSA
QDSLIAKGTSTALQVTAIFDDGTNMDITDSTSIVSDSQAVVEVQGNRSRGISLGASTLQ
AEYKGLHSQLRITVTSATLDSIQVTSLDRDSLPKGLNRQFSAIGIFSDGSHQDLSDDPLT
IWSSSDSSLVRVNDSGLASGVNLGTAHIHASFGSKRGSATMTVGSATLSSIEVTPVNSN
LPLGKKQQLIATGIYSDNSNKDISSLVTWDILDNTIATIQPKGMVETVSTGSTTVLASF
GSSVGSTTLNVVSASLVSISVSSVNSSKAKGLKENFTATGIFSDDSNLDITNQVTWSSS
DTNILIISNSSGSHGSGSALNQGVVKVIASVGGIEGSMDFTVTQAALVSISVSPVLLSM
PKGLTQQFKAMGIFTDNSKQDITSSVTWTSSSKALSVSNVSGREGMGQALAVGSATV
AATLGRTSGKTTIKVAPAILASIQISPMNTTALAKGLKKSFSARGIYSDNSSSDITSSVT
WFSSDPSVAVVGNVPSYKGEVRGEKIGTTNIKAALGNVSSPIVALSVTEAELVSIQVSP
YVSVTPKGITKNFKATGTFTDYSTQDITEQVTWKSSDTEIISIENAAGNKGLAHMLKQ
GDSYITATLGSISSSPELAMVASPTIVSVAVTPSNPSVVKGLTCQFKATATYTDNSTADI
TSMVSWSSSNSNKALVGNDILSGGLVTAVATGSANITARYENLSGSSAVNVTPATLTS
IEVTPVFPSVAKGLTEQFTATGIYSDKSTQDLTQVVTWISSDSSRVAIENTAGKKGLAL
ASTLGSSNIRATYNSIQSSPISMTVTEAKLVSITVSPEFTSKALGLTQQFKAKGIFTDGSE
RDITNLVTWFSSEPLVADAINADENRGLAVSHSIGSTEIHAYYDSVESNSVNFKVTSSE
LVSIEISPENGDLIKGLNQQYTAFGVYSDGSLQDISNSVTWYSSNTSSVSISNAVGSKG
KATALQVGTSKITATYRSVSGTTDLNVSAAILSSIVVSPTKPNVESTSKTKFFAVGMYS
DGTKKDLTSSVTWFSSSTNASVSNALKSKGLVVAGSGTGYSTITATYGSISGNTLLIVN
KYNKAVPTVKSVTSLSPTAIRIVYSEFVNNKEALKLSNYKVVDSSSLVGSCFDNADFK
KNSQTRDFSLKSISGAGDTFTITLSGSQNSGKVYTLIVNKPGIHDRSYAPQSLGCPNNA
DFVGKEQLKLTNAICNSVNRVIVTFSKPLYTGNDIAKSAECSNPSQCKSRYKFAGVSV
LGDVTSAKILNGKVCGGAPADPSKVCLTHTLLQSGGHYTVMAANRLDGDGFDND
VWGAISDSSGQEALQPSPKDRANFVGCGGSPVNFADGPVISDPFGDGSSFASLTNYRY
QVYLGPNRKGNQAVRFRYDGTSPESVFFSFAKDAVGEQSSNTALSGISANYVTMGHA
GCTRNSADIVAGCGPDNEDGRGVFATGLLGGRPHMFMAGSKSLGGLDYLYYSSSAD
ADLDFKYIDMGTITGELTAGASSMAVFDNRVYVGFAKKNNRSNAPDFGKITFHTSDS
TRCVIGSNCDATDGQRGRRFRIDRMPYFGGESLDEEYKGRVGSTARLIRTLAAKNNG
NKPNQLGDSTINWGYYVGIDSLFVFKGTLYAANGGFPNSLHNGSIIRSTSANPAPCE
GKNRCSGWEDVAPRSNPKWHNSPDNNWFSLELVKERDLIPADKAFSQFAEFNGRMY
ATRTICVTSEDRSGLRKSLQTVKGCTDGSYTNRRPQLWKCDPTLSGNKSTCDSGDWS
VVGDDGTGITNFGNVFNHSITMLVANGSYLYVGFDNENGIQIWRTNLQNPGSSSSGW
EQVGGDGLGDVTNRRIYSGITVPKLSLNYVYVSTGGNNRPVKVYRQQNR 
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Table 3.2: The list of all T cell epitopes found in the most antigenic LigB protein (UniProtKB ID Q04JY5) as predicted by 
NetMHCII v2.2 server. All the epitopes were associated with all the three types of HLA alleles namely, HLA-DP, HLA-DQ, and 
HLA-DR. The affinity score of the epitope to the corresponding alleles is in the bracket. 
No. Predicted T cell epitopes Interacting MHC-II (HLA) alleles & 
affinity score (nM) 
1 AALVSISVSPVLLSM HLA-DPA10301-DPB10402 (44.6) 
HLA-DQA10102-DQB10602 (41.5) 
HLA-DQA10501-DQB10301 (44.9) 
HLA-DRB10101 (7.0) 
HLA-DRB10701 (17.8) 
HLA-DRB10901 (36.1) 
HLA-DRB40101 (47.9) 
2 DPSKVCLTHTLLQSG HLA-DPA10301-DPB110402 (39.9) 
HLA-DQA10102-DQB10602 (39.6) 
HLA-DRB10701 (31.9) 
3 IDSLFVFKGTLYAAN HLA-DPA10103-DPB10401 (13.5) 
HLA-DPA10103-DPB10201 (9.5) 
HLA-DPA10103-DPPB10301 (37.1) 
HLA-DQA10501-DQB10301 (19.2) 
HLA-DRB10101 (16.8) 
4 LFVFKGTLYAANGGF HLA-DPA10103-DPB10401 (18.4) 
HLA-DPA10103-DPB10201 (14.6) 
HLA-DQA10501-DQB10301 (24.9) 
HLA-DRB10101 (41.0) 
5 LVSISVSPVLLSMPK HLA-DPA10301-DPB10402 (41.1) 
HLA-DQA10102-DQB10602 (25.6) 
HLA-DRB10701 (30.9) 
6 SLFVFKGTLYAANGG HLA-DPA10103-DPB10401 (17.3) 
HLA-DPA10103-DPB10201 (13.2) 
HLA-DQA10501-DQB10301 (22.0) 
HLA-DRB10101 (21.8) 
7 SRYKFAGVSVLGDVT HLA-DPA10301-DPB10402 (48.4) 
HLA-DQA10501-DQB10301 (26.5) 
HLA-DRB10101 (25.7) 
HLA-DRB10405 (44.8) 
HLA-DRB10701 (19.0) 
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3.5 T cell epitopes in the conserved regions 
 
Figure 3.4: All the T cell epitopes were mapped to the consensus residues in the LigB protein. All of the epitopes are in the highly 
or moderately conserved regions of LigB protein. 
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Table 3.3: The percentage identity of the T cell epitopes to the conserved region of LigB protein. The consensus amino acid 
sequences that correspond to the respective predicted epitope was boxed. The underlined residues are the residues in the epitope that 
vary from the consensus amino acid sequences.  
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Figure 3.5: The target of the vaccine (in red circle) was predicted to be in the part of LigB that is exposed to the external 
environment and more likely to be seen and recognised by the immune cells. The 3D structure of the LigB protein was predicted 
using the most antigenic LigB sequence (Q04JY5) using RaptorX server. The location of the residues in the membrane was 
predicted by TMHMM v.2.0. 
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3.6 Peptide-HLA docking result 
 
The stereo chemical quality of the 3D structure of the chosen peptide vaccine 
(“DSSKICLTHSLLQSG”), as shown in Figure 3.6, was assessed using PROCHECK 
tool.  The Ramachandran plot generated from the analysis showed that >90% of 
residues are in the allowed region (Figure 3.7). 
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Figure 3.6: The predicted 3D structure of the vaccine candidate, modelled by PEP FOLD server. The ribbon representation suggests 
that the peptide vaccine has a core with coil structure while both ends contain helical structure. The hydrophobicity surface indicates 
that the peptide core is made of hydrophobic residues (red) while the ends have more hydrophilic residues (blue and white). The 
structures are visualised by Chimera. 
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Figure 3.7: PROCHECK statistics was checked to validate the 3D structure. The Ramachandran plot suggests that none of the 
amino acids in the peptide vaccine is in the disallowed region. Therefore, the predicted structure was good for the in silico analysis. 
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Figure 3.8a: The schematic diagram of general MHC Class II molecule in human. The molecule is made of two chains (α chain is 
coloured red while β chain is coloured blue). Each chain is folded into two domains. Figure 3.8b: The ribbon representation of the 
HLA-DR1 molecule. The 3D structure was taken from the crystallised HLA-DR1 molecule taken from PDB with the ID of 1KLU.  
 
 
 
 
 
 
 
 
 
Figure 3.8a          Figure 3.8b 
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Figure 3.9: The ribbon representation of a vacant binding-groove of HLA-DR1 molecule. The sides of the groove are made of two 
α-helices (red) while the floor is made of eight antiparallel β-pleated sheets (blue). Both ends of the groove are open-ended.  
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Figure 3.10: The HLA-DR1 molecule before and after the peptide vaccine was docked to it. The peptide vaccine (yellow) is 
predicted to occupy the binding groove of the HLA-DR1 molecule. 
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Figure 3.11: The peptide vaccine-HLA-DR1 complex from side view (left) and top view (right). The image on the right is probably 
the view of the peptide-HLA complex as ‘viewed’ by the immune cells. 
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Figure 3.12: The peptide vaccine (grey) occupying the binding pockets of the HLA-DR1 molecule. Pocket 1 (yellow), Pocket 4 
(cyan), Pocket 6 (white), Pocket 7 (orange), and Pocket 9 (green) are made of residues that interact with residues in the peptide 
vaccine. The pockets are coloured according to PPD (Program for Pocket Definition) Pocket Compositions (Androulakis et al, 
1997).  
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Figure 3.13a shows the peptide vaccine (yellow) in the binding groove of the HLA-DR1 molecule. Figure 3.13b illustrates the 
molecular interactions between the residues in the peptide vaccine and the residues in the HLA-DR1 molecule. The bonds in the 
peptide vaccine (magenta); residues that make hydrophobic contacts (red-spoked arcs); hydrogen bonds (dashed green lines). 
 
 
 
 
 
 
 
 
Figure 3.13a 
Figure 3.13b 
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Table 3.4: The residues that are involved in the hydrogen bonding that holds the peptide-vaccine in the peptide-binding groove of 
HLA-DR1 molecule. The length between the atoms of the participating residues is predicted by LigPlot software. 
 
Residues in HLA Residues in peptide Length (Å) 
Gly-9 His-9 3.15 
Gln-70 Leu-12 2.69 
Arg-71 Leu-7 2.72 
Arg-71 Cys-6 3.15 
Arg-71 Cys-6 2.04 
Thr-77 Ser-14 2.78 
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Figure 3.14: The 3D representation showing the interactions between the residues in the peptide vaccine and amino acids in the 
binding-pockets of HLA-DR1 molecule. Peptide vaccine (yellow), residues in the HLA molecule (grey sticks) making hydrogen 
bonds (cyan lines) residues in the HLA molecule (white sticks). The number on the cyan line is the distance (in Å) between the 
residues that form hydrogen bonds. The residues making hydrophobic interactions are surrounded by diffused white clouds.  
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CHAPTER 4   
 
DISCUSSION 
 
4.1 LigB protein as the target for vaccine 
 
Leptospirosis, which is one the most important bacterial infections that has cost the 
lives of humans and livestock worldwide, requires an improved vaccine since the 
existing vaccines can only provide suboptimal protection. Although the disease can be 
easily treated with a prescription of antibiotics, the use of prophylactic vaccine to 
prevent the bacterial diseases is more appealing. The former could potentially lead to 
antibiotics resistance problem, which is harder to tackle once the pathogenic bacteria 
mutate and the existing antibiotics are no longer effective against the pathogens. 
Overexposure of the antibiotics to the bacteria will only give an advantage to the 
bacteria to be ahead of us in the antibiotics arms race. Furthermore, antibiotics are only 
effective if the disease is diagnosed and detected early. This is not always the case with 
leptospirosis because the symptoms of the disease are rather indistinguishable from 
those of other non-life-threatening diseases. 
 
In the current study, an attempt to computationally design a peptide-based 
vaccine based on a recently discovered antigenic outer-membrane protein, LigB, was 
undertaken. Thirty-two LigB sequences were successfully retrieved from UniProtKB 
database. More than 80% of LigB sequences available in the database were partial 
sequences (having less than 300 amino acids) and had to be disregarded, leaving only 
complete or almost complete sequences (having length of greater than 1400 amino 
acids) that were amenable for the analysis. This stringent requirement was set to avoid 
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some consensus regions to be missing out from the analysis. As a result, only 17 unique 
pathogenic serovars (Lai, Pyrogenes, Bulgarica, Grippotyphosa, Pyrogenes, 
Medanensis, Bataviae, Zanoni, Copenhageni, Icterohaemorrhagiae, Canicola, Pomona, 
Kennewicki, Bim, Valbuzzi, Panama and Hardjo-bovis) were covered. Nevertheless, 
this number is adequate for the purpose of the study. Ideally, attempts to sequence the 
complete LigB proteins could be made for other obscured pathogenic serovars to give 
wider coverage of pathogenic Leptospira serovars for the future analysis and unveil 
more accurate representation of the conserved regions in LigB protein.  
 
 The immune cells need to be primed to recognise the part of the protein from the 
pathogen that is directly exposed to them. Therefore, the choice of LigB protein as the 
target for the vaccine is relevant. LigB protein is purported to be a transmembrane 
protein and it is only present in pathogenic species. Based on the analysis, the proposed 
peptide vaccine is supposed to activate the naïve helper T cells to induce Th2 response, 
which will mediate the activation and maintenance of the humoral immune response 
against the extracellular pathogenic Leptospira sp. Neutralising antibodies specific to 
the conserved region of the LigB protein will impede the function of LigB, which 
serves as a vital gateway to the host cell. This will effectively prevent the bacteria from 
invading the host cell. Most importantly, the protein has been predicted to contain 
several T cell epitopes, which means that the protein is likely to be presented to the 
helper T cell. The fact that the peptide vaccine is designed to be as identical as possible 
to the conserved region of the LigB proteins for all pathogenic serovars means that the 
vaccine could be effective against broader pathogenic serovars. Nevertheless, the 
effectiveness of the vaccine, along with its potential in causing allergenicity, needs to be 
confirmed in vivo and in vitro studies in the future.  
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 The use of LigB sequence from L. borgpetersenii of serovar Hardjo-bovis and 
strain L550 in the prediction of T cell epitopes is apt because it has been predicted to be 
the most antigenic protein by VaxiJen, an antigenicity predictive server. Furthermore, 
serovar Harjo-bovis is suggested to be the most commonly implicated serovar in 
leptospirosis in dairy farmers, slaughterhouse workers, and animal-associated 
occupations (Black et al, 2001). Hence, an improved leptospirosis vaccine for these 
workers, who are at high risk of obtaining the infection from the infected animals, is 
urgently needed. The current vaccine against serovar Hardjo-bovis is only effective 
against that particular serovar. It is hoped that the improved vaccine will provide, not 
only protection against serovar Hardjo-bovis, but also against other pathogenic serovars. 
 
4.2 Future direction of the study 
 
An individual inherits MHC or HLA genes in a Mendelian fashion from each parent as 
an HLA haplotype. The highly polymorphic nature of HLA molecules is attributed to 
the HLA loci, which are known to be the most polymorphic loci known in higher 
vertebrates. The polymorphism of HLA gives rise to the peptide-binding specificity, 
which is dictated by a limited number of amino acid residues in the peptide-binding 
pockets (Choo et al, 2007). To verify that the peptide vaccine can, at least, bind to the 
HLA molecule in silico, a rigid docking could be conducted between the designed 
peptide vaccine and an HLA molecule. 
 
In the current study, the structure-based analysis revealed that the predicted 
peptide could accommodate the binding-groove of an HLA molecule. Several forces 
such as hydrogen bonds and hydrophobic interactions were predicted to be the forces 
that are responsible to stabilise the peptide in the groove to be presented to helper T 
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cells. According to the rigid docking analysis, hydrophobic interactions are the forces 
that stabilise the peptide vaccine in the binding groove. The additional forces that are 
predicted to be present are hydrogen bonding, which involved several residues in the 
peptide vaccine and the residues in the HLA-DR1 molecule. Arg-71 residue in the β-
chain (Pocket 4) of the HLA molecule is the residue that is majorly involved in the 
hydrogen bonding to hold the peptide in the binding pocket. A non-synonymous 
mutation that results in the change of the Arg-71 residue could potentially alter the 
interaction of the whole peptide with the HLA molecule, subsequently reduce the 
probability of the peptide to form a complex with an HLA molecule and ultimately 
diminish the effectiveness of the designed vaccine. 
 
The distribution and frequency of HLA alleles can vary greatly among different 
ethnic groups. This factor, along with the polymorphism in the HLA structure itself, 
complicate the in silico development of the vaccine. However, the two factors need to 
be considered to determine how well the peptide vaccine will fare as an effective 
vaccine in individuals with diverse genetic background. In the future, the variability of 
HLA molecules resulting from different HLA haplotypes needs to be taken into 
account. For example, instead of docking the designed peptide vaccine to a single type 
of HLA molecule, a predicted 3D structure of HLA molecule, which represents all 
HLA-DR, HLA-DQ, and HLA-DP molecules, can be used. The predicted structure, 
which can be generated by homology modelling, will give a better and meaningful 
prediction. However, the accuracy of the structure relies on the template model used and 
the availability of the HLA sequences in the database. The future study should also 
consider the variability of the residues in the binding pockets of the HLA sequences 
among individuals in different ethnics. Since leptospirosis susceptibility was reported to 
have an association with a certain HLA haplotype (Lingappa et al, 2004), a closer look 
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at the molecular interaction of leptospiral peptide with the HLA molecule from 
susceptible individual and non-susceptible individual can be done to design an 
improved peptide vaccine that can give protection to all individuals, regardless of their 
HLA haplotype.  
 
 As of 2008, a total of 986 alleles for Class II molecules (HLA-DR, HLA-DP, 
HLA-DQ) was recorded and deposited in IMGT/ HLA Database release 2.22 (Shiina et 
al, 2009). This number is predicted to grow in years to come. Hence, the developers of 
the T cell epitope predictive tools need to revise and update their servers regularly. The 
current study was able to cover only 2.5% of the HLA alleles reported in the current 
IMGT/ HLA database. The author is aware of the limitations of in silico studies because 
all of the training data sets used in the T cell epitope prediction tool have been derived 
from laboratory experiments. The reliability of in silico methods relies heavily on the 
quantity and most importantly the quality of the experimental data. Although more 
HLA alleles are discovered and added into the IMGT/ HLA database every year, the 
results of the experiments that establish the association of peptides with the newly 
found alleles, are underreported and cannot be included in the training data. 
Immunologists who work in the laboratory should be encouraged to share their results 
with the bioinformaticians community to enable bioinformaticians to design a more 
accurate mathematical algorithm or improve the existing predictive tools. The concerted 
effort between immunologists and bioinformaticians will benefit both communities as 
well as humankind with the fast discovery of much more improved vaccine to eradicate 
or at least reduce the mortality rate caused by global infectious disease such as 
leptospirosis. 
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CHAPTER 5 
 
SUMMARY 
 
The present study has shown that an integrated computational approach could be used to 
predict an improved peptide-based vaccine candidate against bacterial pathogen, 
Leptospira sp, which is the causative agent of leptospirosis.  Unlike traditional method, 
rational design and in silico studies can vastly minimise unnecessary trial and error 
repeats, thus saving time and cut costs for the vaccine development. Several publically 
available bioinformatics tools have been utilised in the research. The sequence-based 
analysis and structure-based analysis revealed that the epitope with the sequence of 
‘DSSKICLTHSLLQSG’ could be the best peptide-based vaccine candidate. The peptide 
is predicted to be likely to be presented by MHC Class II in human and more likely to 
induce an immune response. The target of the vaccine is present in all pathogenic 
serovars of Leptospira and is predicted to be in the conserved region of LigB protein 
that is exposed to the external environment, thus, more likely to be recognised by T 
helper cells. Having known the sequence of the potential peptide vaccine, the vaccine 
can be synthesized using organic chemistry for experimental validation.  
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APPENDIX 
 
 
 
 
A snapshot of output given by NetMHCII v.2.2 server. The 15-mer peptides/ T cell epitopes (column 3), the corresponding HLA-
DP alleles (column 1) and the affinity score (column 6) were used in the analysis. Only short binders were considered in the study. 
Similar outputs were also generated for HLA-DQ alleles and HLA-DR alleles. 
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Few Shell scripts used to process the raw outputs generated by NetMHCII v.2.2 
 
 
 
 
 
 
 
